

**EFFECT OF ASPIRIN PRETREATMENT IN STREPTOZOTOCINE
INDUCED TYPE-II DIABETIC RATS**

**Srinivas Martha¹, Krishna R. Devarakonda¹, Rama Narsimha Reddy. Anreddy¹ and
Narayana Pantam^{*2}.**

¹Dept. of Pharmacology and Clinical Pharmacy, University College of Pharmaceutical Sciences, Kakatiya University, Warangal – 506 009, Andhra Pradesh, INDIA.

²Department of General Medicine, Mahatma Gandhi Memorial Hospital, Warangal – 506 002, Andhra Pradesh, INDIA.

Summary

In the present study, we made an attempt to investigate whether aspirin plays any role in preventing type-2 diabetes mellitus in rats. Rat pups were divided in to four groups, on 5th day of their birth, group-I pups were received citrate buffer solution served as normal, group-II were treated only with streptozotocin (80mg/kg, *i.p*) served as diabetic, group-III & group-IV were treated with aspirin (10mg/kg/day, *p.o*) for one month (5-35 days) and two month (5-65) after streptozotocin served as treated groups. On 36 and 66 day, blood samples were collected from all animals and fasting blood sugar, fasting insulin, insulin resistance and insulin sensitivity levels were estimated. Results of 36 & 66 days blood samples of pups treated with streptozotocin alone and in combination with aspirin for one month and two months were shown significantly raised body weight, fasting blood glucose and insulin resistance levels (P=0.0005, P<0.0001, P<0.0001, P=0.0006, P<0.0001, P=0.0030) and significantly lowered fasting insulin and insulin sensitivity levels when compared to the normal control pups (P<0.0001, P<0.0001, P<0.0001, P<0.0001, P<0.0001, P=0.0068) respectively. The present study indicates that aspirin pretreatment seems to protect pancreas from damage caused by streptozotocin and maintains glucose levels in diabetic rats and increases insulin sensitivity and reduces insulin resistance.

Keywords: Streptozotocin, glucose, insulin and type-2 diabetes.

Correspondence Address:

Dr. PANTAM NARAYANA, M.D.

Professor of Medicine,

Department of General Medicine,

Mahatma Gandhi Memorial Hospital,

Warangal – 506 002, Andhra Pradesh, INDIA.

Work: +91-870-2423-059, Mobile: +91-9849323025

Fax: +91-870-245-3508.

E-mail: pantamnarayana@gmail.com

Introduction

Type-2 diabetes mellitus is a metabolic disorder with characteristics of hyperglycemia and insufficiency of secretion or action of endogenous insulin [1]. Insulin resistance is one of the major characteristics of type 2 diabetes mellitus. If the insulin resistance can result from oxidative damage, then a prediction would be that chronic oxidative stress would lead to hyperinsulinaemia if plasma glucose is clamped at normal level by infusing the required insulin. Increased oxidative stress, defined as a persistent imbalance between the production of highly reactive molecular species (chiefly oxygen and nitrogen) and antioxidant defenses, is a widely accepted participant in the development and progression of diabetes and its complications [2]. Hyperglycemia was also found to promote lipid peroxidation of low density lipoprotein (LDL) by a superoxide-dependent pathway to generate free radicals [3]. Free radicals can be generated in glucose oxidation, which is believed to be the main source of free radicals, which are not degraded by catalase or glutathione peroxidase, and in the presence of transitional metals, can lead to production of extremely reactive hydroxyl radicals [4]. Aspirin is a derivative of salicylic acid, used as a NSAID, anti thrombotic, antioxidant and anti diabetic drug has new approach in type2 diabetes. Salicylates inhibit serine/ threonine caused insulin resistance and IKK- β activity and restore insulin sensitivity, both *in-vitro* and *in vivo*. Salicylates alter the phosphorylation patterns of IRS proteins, resulting in the decrease serine phosphorylation, increased tyrosine phosphorylation, and improved insulin action [5]. The principal mechanism of action of aspirin for its pharmacological actions is inhibition of arachidonate cyclooxygenase [6]. Cyclooxygenase (COX) is of two types namely COX-I & COX-II. COX-I is a constitutive enzyme expressed in most tissues including

blood platelets and is involved in cell-cell signaling and tissue homeostasis. COX-II is induced in inflammatory cells when they are activated and is believed to be the enzyme that produces the prostanoid mediators of inflammation. Aspirin and also most of the non-steroidal anti inflammatory drugs (NSAIDS) in current use are inhibitors of both isoenzymes (COX-I & COX-II), though they vary in the degree of inhibition of each [7]. Many of the antioxidants have the capability of decreasing the blood sugar levels. Free radicals play a major role in most of the diabetes and cardiovascular diseases. Aspirin with its antioxidant properties is considered to be beneficial in such disorders [8].

In view of the above facts, in the present study, we made an attempt to investigate whether aspirin plays any role in preventing type-2 diabetes mellitus in rats.

Materials and Methods

Materials: Aspirin pure substance was a kind gift from Natco Pharma Limited, Hyderabad, India. Diphenyl picryl hydrazyl and streptozotocin were purchased from Sigma, St. Louis, USA. Glucose kit was purchased from Excel diagnostics limited, Hyderabad. Ethanol (analytical grade) purchased from E. Merck Limited, Mumbai, India.

Animals: 4 Pregnant Female Wistar rats, weighing between 300-350g were obtained from Mahaveer Enterprises, Hyderabad. The rats were housed individually in acrylic cages in standard environmental conditions (20-25⁰C), fed with standard rodent diet and water *ad libitum*. The rats were delivered within 1-2 days. The experiments on animals were conducted in accordance with the internationally accepted principles for laboratory animal use. The experiment was planned after getting the approval from the Institutional animal ethical committee.

Induction of diabetes: On morning 8.00 AM, the rat Pups (5th day old) were received a single 80 mg/kg intraperitoneal injection of streptozotocin (Sigma, St. Louis, MO) in 0.1 M sodium citrate buffer, pH 4.5. After 8th week, animals with blood glucose levels greater than 150 mg/dl were considered diabetic [9].

Study design: Rat pups (neonates) were divided in to four groups, group-I contains 14 pups, group-II 8 pups, group-III 7 pups and group-IV 9 pups. On the day 5, group-I pups were received citrate buffer solution served as normal control group, group-II treated only with streptozotocin (80mg/kg, *i.p*) served as diabetic control, group-III treated with aspirin (aspirin dissolved in small volume of ethanol and finally make up with milk) (10mg/kg/day, *p.o*) for one month (5-35 days) after streptozotocin served as treated group for one month and group-IV treated with aspirin (aspirin dissolved in small volume of ethanol and finally make up with milk) (10mg/kg/day, *p.o*) for two months (5-65 days) after streptozotocin served as treated group for two months. On day 35 and 65, blood samples were collected from all the animals and fasting blood sugar levels, fasting insulin levels, insulin resistance and insulin sensitivity levels were estimated for one month and two months. Insulin resistance was assessed by using the previously validated homeostasis model assessment for insulin resistance, calculated from the fasting insulin and fasting glucose concentrations according to the formula [10]:

$$\text{HOMA-IR} = \text{FI in mU/l or } \mu\text{U/ml} \times \text{FPG in mg/dl} / 405$$

Similarly, insulin sensitivity was assessed by using the previously validated homeostasis model assessment for insulin sensitivity, calculated from the fasting insulin and glucose concentrations according to the formula [10]:

$$\text{HOMA-S} = 1/\text{HOMA-IR}$$

Statistical analysis: All variables are expressed as means \pm SD. Group differences of continuous variables were compared using ANOVA followed by Newman Keuls test. For all analyses, a P value < 0.05 was considered to be statistically significant. All analyses were performed using Graph Pad Prism 4.

Results

35 & 65 days blood samples of pups treated with streptozotocin alone and in combination with aspirin for one month and two months were shown significantly raised body weight, fasting blood glucose and insulin resistance levels when compared to the normal control group of pups (P=0.0005, P<0.0001, P<0.0001, P=0.0006, P<0.0001, P=0.0030) respectively. Pups treated with streptozotocin alone and in combination with aspirin for one month and two months were shown significantly lowered fasting insulin and insulin sensitivity levels when compared to the normal control group of pups (P<0.0001, P<0.0001, P<0.0001, P<0.0001, P=0.0068) respectively.

Table No – 1: Effects of aspirin on various biochemical parameters

Parameter	Normal		Diabetic		Aspirin treated for				P-Value	
	8 th Week	10 th Week	8 th Week	10 th Week	One Month		Two Months		8 th Week	10 th Week
					8 th Week	10 th Week	8 th Week	10 th Week		
Sex (M/F)	4M/8F	4M/8F	3M/5F	3M/5F	2M/5F	2M/5F	4M/5F	4M/5F		
Body Weight(g)	104.58 ± 14.37	99.58 ± 20.94	118.75 ± 15.53	130.63 ± 29.93	138.57 ± 18.64	144.29 ± 19.24	106.67 ± 16.58	111.11 ± 15.16	0.0005	0.0006
Glucose (mg%)	77.09 ± 14.15	77.75 ± 7.33	207.26 ± 14.33	170.46 ± 26.61	117.19 ± 28.04	127.75 ± 34.19	112.87 ± 10.54	115.71 ± 23.43	P<0.0001	P<0.0001
Insulin (µg/L)	1.89 ± 0.14	1.86 ± 0.14	1.21 ± 0.17	1.19 ± 0.16	1.59 ± 0.09	1.57 ± 0.09	1.62 ± 0.12	1.59 ± 0.11	P<0.0001	P<0.0001
HOMA-IR	8.6 ± 1.29	8.63 ± 0.87	14.89 ± 1.99	12.06 ± 2.44	11.25 ± 3.10	12.06 ± 3.45	10.92 ± 1.14	10.91 ± 1.84	P<0.0001	0.0030
HOMA-S	0.12 ± 0.02	0.12 ± 0.01	0.07 ± 0.01	0.09 ± 0.02	0.10 ± 0.03	0.09 ± 0.03	0.09 ± 0.01	0.09 ± 0.02	P<0.0001	0.0068

[All variables are expressed as means ± SD. Group differences of continuous variables were compared using ANOVA followed by Newman Keuls test. For all analyses, a P value < 0.05 was considered to be statistically significant.]




Figure-1. Fasting glucose levels of study animals




Figure-2. Fasting insulin levels of study animals




Figure-3. Insulin sensitivity levels of study animals

Discussion

Yaun et al., 2001 reported Salicylates inhibits IKK-B activity and restore insulin sensitivity, both *invitro* and *invivo* [5]. Hundal et al., 2001 reported treatment of nine type 2 diabetic patients for 2 Weeks with high dosages of aspirin (7g/day) resulted in reduced hepatic glucose production and fasting hyperglycemia and increased insulin sensitivity [11]. Micossi et al., 1947 reported aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects [12]. Seino et al., 1982 reported that acetyl salicylic acid (ASA) alleviates glucose intolerance in maturity onset diabetics by a direct enhancement of insulin secretion [13]. Our present study also indicates that the aspirin treated for one month shown that significantly reduced blood glucose levels, significantly improved levels of insulin, significantly improved levels of insulin sensitivity and significantly lowered insulin resistance levels. There is a great deal of evidence that aspirin/NSAIDs have effects on insulin resistance. It has been long known that salicylates have a hypoglycemic effect and that they reduce

fasting blood glucose in diabetic persons [14-18]. High doses of salicylates have been shown to reverse hyperglycemia, hyperinsulinemia, and dyslipidemia in obese rodents by sensitizing insulin signaling [19]. In patients with type 2 diabetes, aspirin treatment has been shown to reduce fasting plasma glucose, total cholesterol, C-reactive protein, triglycerides, and insulin clearance; aspirin reduced hepatic glucose production and improved insulin-stimulated peripheral glucose uptake by 20% [20]. Aspirin/NSAID influence on insulin resistance appears to be independent of COX-2 inhibition, instead involving inhibition of nuclear factor- κ B and I κ B and/or activation of peroxisome proliferator-activated receptors [19].

An interaction between aspirin and IRS1 in antagonizing effects of tumor necrosis factor- α (TNF- α) has also been reported. TNF- α , a major cause of insulin resistance in obesity and inflammation, has been reported to inhibit insulin-induced glucose uptake by targeting components of the insulin signaling cascade, one of which is insulin receptor substrate [21-25]. IRS1 is the major cytoplasmic substrate of the insulin receptor in most insulin sensitive tissues and is necessary for maintenance of metabolic homeostasis. Aspirin has been shown to inhibit the TNF- α -induced serine phosphorylation of IRS1 through inhibition of multiple serine kinases, including I κ B kinase [20]. The conclusions of present study indicates that aspirin pretreatment seems to protect pancreas from damage caused by STZ and maintains glucose levels in diabetic rats and increases insulin sensitivity and reduces insulin resistance. The protection offered by the aspirin treatment in type -2 diabetes, there may inhibition of IKK- β activity and alters the phosphorylation patterns of IRS proteins resulting in the decrease serine phosphorylation, increased

tyrosine phosphorylation, improved insulin action and restore insulin sensitivity. Further studies in humans are required to prove this hypothesis.

Acknowledgement

The first author is grateful to Rajiv Gandhi National Fellowship from the University Grants Commission (UGC), India for providing Senior Research Fellowship.

References

1. Kataoka S, Satoh J, Fujiya H, Toyota T, Suzuki R, Itoh Kumagai K. Immunological aspects of the nonobese diabetic (NOD) mouse: Abnormalities of cellular immunity. *Diabetes* 1983; 32:247-253.
2. Ceriello A. Oxidative stress and glycemic regulation. *Metab* 2000; 49:27-29.
3. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxy radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. *Diabetes* 1994; 43:1010-1014.
4. Jiang ZY, Wollard AC, Wolff SP. Hydrogen peroxide production during experimental protein glycation. *FEBS Lett* 1990; 268:69-71.
5. Yaun M, Konstantopoulos N, Lee J, Hanse, L, Li ZW, Kirin M, Shoelson SE. Reversal of obesity and Diet-induced insulin resistance with salicylates or targeted disruption of IKK B. *Science* 2001; 293:1673-1677.
6. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nature New Biology* 1971; 231:232-235.
7. Gierse James K, McDonald Joseph J, Hauser Scott D, Rangwala Shaukat H, Koboldt Carol M, Seibert Karen. A single amino acid differences between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitor. *The Journal of Biological Chemistry* 1996; 271:15810-15814.

8. Burak Pamukcu. Review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. *Journal of Thrombosis and Thrombolysis* 2007; 23(3) 45-50.
9. Arulmozhi DK, Veeranjanyulu A, Bodhankar SL, Neonatal streptozotocin-induced rat model of Type 2 diabetes mellitus: A glance. *Indian Journal of Pharmacology* 2004; 36(4):217-221.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β -cell function from fasting glucose and insulin concentrations in man. *Diabetologia* 1985; 28:412-419.
11. Hundal RS, Mayerson AB, Peterson KF, Rife FS, Randhawa PS, Inzucchi SE, Shoelson SE, Shulman GI. Potential for novel classes of insulin sensitizing agents by inhibition of IKKB activity. *Diabetes* 2001; 50(2):A117.
12. Micossi P, Pontiroli AE, Baron SH, Tamayo RC, Lengel F, Bevilacqua M, Raggi U, Norbiato G, Foa PP. *Diabetes* 1978; 27(12):1196-1204.
13. Seino Y, Usami M, Nakahara H, Takemura J, Nishi S, Ishida H, Ikeda M, Imura H. Prostaglandins. *Leukot Med* 1982; 8(1):49-53.
14. Fang V, Foye WO, Robinson SM, Jenkins HJ. Hypoglycemic activity and chemical structure of the salicylates. *J Pharm Sci* 1968; 57(12):2111 –2116.
15. Graef I, Gibbons DM. Salicylates and carbohydrate metabolism. *Diabetes* 1960; 9:416 –418.
16. Powell ED, Field RA. Studies on salicylates and complement in diabetes. *Diabetes* 1966; 15(10):730 –733.
17. McRae JR, Chen M, Robertson RP. Improvement of defective insulin responses to glucose, arginine, and b-adrenergic stimulation in diabetics by sodium salicylate. *Adv Prostaglandin Thromboxane Res* 1980; 8:1287-1289.
18. Baron SH. Salicylates as hypoglycemic agents. *Diabetes Care* 1982; 5(1):64 – 71.
19. Yuan M, Konstantopoulos N, Lee. J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKb. *Science* 2001; 293(5535):1673 –1677.

20. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. *J Clin Invest* 2002; 109(10):1321 – 1326.
21. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. *J Biol Chem* 2003; 278(27):24944 – 24950.
22. Xu H, Hotamisligil GS. Signaling pathways utilized by tumor necrosis factor receptor 1 in adipocytes to suppress differentiation. *FEBS Lett* 2001; 506(2):97 – 102.
23. Hotamisligil GS. The role of TNF- α and TNF receptors in obesity and insulin resistance. *J Intern Med* 1999; 245(6):621 – 625.
24. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF- α - and obesity-induced insulin resistance. *Science* 1996; 271(5249):665 – 668.
25. Hofmann C, Lorenz K, Braithwaite SS, et al. Altered gene expression for tumor necrosis factor- α and its receptors during drug and dietary modulation of insulin resistance. *Endocrinology* 1994; 134 (1):264 – 270.